Market cap
$0 Mln
Revenue (TTM)
$2 Mln
P/E Ratio
--
P/B Ratio
0.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-2.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-7.3
-
Face value
--
-
Shares outstanding
4,443,040
8 Years Aggregate
CFO
$-103.45 Mln
EBITDA
$-116.07 Mln
Net Profit
$-118.59 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Tff Pharmaceuticals Inc (TFFP)
| 0.0 | 0.0 | -79.9 | -98.9 | -92.8 | -77.9 | -- |
|
BSE Sensex*
| -10.8 | -3.8 | -8.5 | -8.0 | 6.9 | 8.6 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|
|
Tff Pharmaceuticals Inc (TFFP)
| -99.1 | -73.3 | -88.2 | -38.1 | 167.7 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Tff Pharmaceuticals Inc (TFFP)
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus... on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas. Read more
-
President, CEO & Director
Dr. Harlan F. Weisman
-
President, CEO & Director
Dr. Harlan F. Weisman
-
Headquarters
Fort Worth, TX
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Tff Pharmaceuticals Inc (TFFP)
What is the current share price of Tff Pharmaceuticals Inc (TFFP) Today?
The share price of Tff Pharmaceuticals Inc (TFFP) is $0.07 (NASDAQ) as of 26-Feb-2025 09:30 EDT. Tff Pharmaceuticals Inc (TFFP) has given a return of -92.76% in the last 3 years.
What is the current PB & PE ratio of Tff Pharmaceuticals Inc (TFFP)?
Since, TTM earnings of Tff Pharmaceuticals Inc (TFFP) is negative, P/E ratio is not available.
The P/B ratio of Tff Pharmaceuticals Inc (TFFP) is 0.09 times as on 26-Feb-2025, a 98 discount to its peers’ median range of 4.31 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-0.66
|
1.47
|
|
2022
|
-0.03
|
0.05
|
|
2021
|
-0.29
|
0.23
|
|
2020
|
-0.78
|
0.38
|
|
2019
|
--
|
--
|
What is the 52 Week High and Low of Tff Pharmaceuticals Inc (TFFP)?
The 52-week high and low of Tff Pharmaceuticals Inc (TFFP) are Rs -- and Rs -- as of 20-May-2026.
What is the market cap of Tff Pharmaceuticals Inc (TFFP)?
Tff Pharmaceuticals Inc (TFFP) has a market capitalisation of $ 0 Mln as on 26-Feb-2025. As per SEBI classification, it is a Small Cap company.
Should I invest in Tff Pharmaceuticals Inc (TFFP)?
Before investing in Tff Pharmaceuticals Inc (TFFP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.